Jianmin Mao

Jianmin brings over 20 years of industrial experience in drug discovery and development. Most recently, as Vice President of CMC at BeyondSpring Pharmaceuticals, he led the CMC team in Plinabulin NDA filings in the US and China. Prior to that, he served as Executive Director at Zikani Therapeutics (now Eloxx Pharmaceuticals), a company focused on developing therapies that treat rare and ultra-rare premature stop codon diseases. As Senior Director at Flatley Discovery Lab (FDL), he was instrumental in advancing the company’s two lead programs from preclinical stage into clinical Phase II. Before joining FDL, he contributed to the successful approval and commercialization of Baxdela® at Melinta Therapeutics. Prior to that, he worked on oncology drug development with ArQule Inc. (now Merck), where he contributed to multiple preclinical and clinical programs, most notably Derazantinib, Miransertib, and Tivantinib. Jianmin received his B.S. and Ph.D. in organic chemistry from Lanzhou University. He is an author of more than 30 peer-reviewed publications and is an inventor on 12 issued patents.